Current Good Manufacturing Practices (cGMP) are essential guidelines established by regulatory agencies like the FDA to ensure the quality, safety, and efficacy of pharmaceutical and biotech products. These standards govern every stage of manufacturing, from facility design to process controls. With the FDA’s ongoing updates and enforcement actions, understanding cGMP expectations is critical for maintaining compliance, protecting public health, and preventing costly recalls or penalties.
- FUD Liner: Are your compliance gaps leaving you vulnerable? Don’t wait for an FDA inspection to discover unmet expectations that could result in devastating fines or production halts.
This webinar offers a thorough exploration of the most pressing cGMP issues identified by the FDA in 2026. Participants will gain a clear understanding of the evolving regulatory landscape and its implications for the pharmaceutical and biotech industries. The session will cover critical inspection trends, recurring compliance pitfalls, and actionable strategies to address regulatory expectations efficiently.
By attending, you’ll learn how to proactively manage risk, enhance operational standards, and foster a culture of accountability across your organization. Real-world examples and expert commentary will equip attendees with the tools necessary to close compliance gaps and exceed FDA expectations, protecting both your operations and your consumers.
WHY SHOULD YOU ATTEND?
2026 introduces new challenges and heightened scrutiny around cGMP compliance as the FDA continues to target key areas of concern within the industry. Staying current with these issues is essential for avoiding warning letters, safeguarding product integrity, and preserving your organization’s reputation.
AREA COVERED
- Overview of cGMP principles and FDA enforcement priorities in 2026
- Common inspection findings and recurring violations
- Strategies for preparing and passing FDA inspections
- Updates on facility requirements, process validation, and documentation
- practices
- Risk-based approaches to ensure ongoing compliance and product quality
- Case studies of cGMP compliance failures and lessons learned
- Best practices for staff training and maintaining a compliance culture
WHO WILL BENEFIT?
- Quality Assurance Managers
- Regulatory Affairs Professionals
- Manufacturing Supervisors
- Compliance Managers
- Clinical Operations Personnel
- Facility Managers
- Target Companies:
- Pharmaceutical Manufacturers
- Biotechnology Firms
- Contract Manufacturing Organizations (CMOs)
- Medical Device Manufacturers
- Over-the-Counter Product Manufacturers
- Nutraceutical and Dietary Supplement Companies
- Target Associations/Societies:
- Pharmaceutical Quality Organizations
- Regulatory Compliance Networks
- Medical Device and Biotechnology Associations
- Controlled Substances Management Groups industry-specific GMP Training Coalitions
- Target Audience to market:
- Individuals in quality assurance, regulatory affairs, manufacturing operations, or compliance who are responsible for meeting cGMP standards and navigating FDA requirements.
2026 introduces new challenges and heightened scrutiny around cGMP compliance as the FDA continues to target key areas of concern within the industry. Staying current with these issues is essential for avoiding warning letters, safeguarding product integrity, and preserving your organization’s reputation.
- Overview of cGMP principles and FDA enforcement priorities in 2026
- Common inspection findings and recurring violations
- Strategies for preparing and passing FDA inspections
- Updates on facility requirements, process validation, and documentation
- practices
- Risk-based approaches to ensure ongoing compliance and product quality
- Case studies of cGMP compliance failures and lessons learned
- Best practices for staff training and maintaining a compliance culture
- Quality Assurance Managers
- Regulatory Affairs Professionals
- Manufacturing Supervisors
- Compliance Managers
- Clinical Operations Personnel
- Facility Managers
- Target Companies:
- Pharmaceutical Manufacturers
- Biotechnology Firms
- Contract Manufacturing Organizations (CMOs)
- Medical Device Manufacturers
- Over-the-Counter Product Manufacturers
- Nutraceutical and Dietary Supplement Companies
- Target Associations/Societies:
- Pharmaceutical Quality Organizations
- Regulatory Compliance Networks
- Medical Device and Biotechnology Associations
- Controlled Substances Management Groups industry-specific GMP Training Coalitions
- Target Audience to market:
- Individuals in quality assurance, regulatory affairs, manufacturing operations, or compliance who are responsible for meeting cGMP standards and navigating FDA requirements.
